Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

201. Controversies in Oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do?

Controversies in Oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do? Controversies in Oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do? | Esmo Open We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Controversies in Oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do

ESMO open2018 Full Text: Link to full Text with Trip Pro

202. Model for Early Detection of Breast Cancer in Low-Resource Areas: The Experience in Peru

Model for Early Detection of Breast Cancer in Low-Resource Areas: The Experience in Peru ');//--> ');//--> Search in: Menu Captcha ASCO Family of Sites Journals Publications Education Other Sites 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2018 American Society of Clinical Oncology |

Journal of global oncology2018 Full Text: Link to full Text with Trip Pro

203. Impact of Breast Cancer Early Detection Training on Rwandan Health Workers’ Knowledge and Skills

Impact of Breast Cancer Early Detection Training on Rwandan Health Workers’ Knowledge and Skills ');//--> ');//--> Search in: Menu Captcha ASCO Family of Sites Journals Publications Education Other Sites 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2018 American Society of Clinical Oncology |

Journal of global oncology2018 Full Text: Link to full Text with Trip Pro

204. Mitochondrial DNA copy number instability in ERBB2-amplified breast cancer tumors

Mitochondrial DNA copy number instability in ERBB2-amplified breast cancer tumors 29743853 2018 11 14 1611-2156 17 2018 EXCLI journal EXCLI J Mitochondrial DNA copy number instability in ERBB2-amplified breast cancer tumors. 149-158 10.17179/excli2017-819 Increase in the copy number of ERBB2 , a Tyrosine Kinase Receptor (TKR) leads to the overexpression of oncogene product and consequently uncontrolled cell proliferation which has been reported in different aggressive cancers with mitochondrial (...) malfunctions. Although, amplification of ERBB2 has been reported in different studies; however, the association between changes in mitochondrial DNA content and the ERBB2 gene copy number is poorly understood. The relative mitochondrial DNA content of breast cancer tumor tissues of 70 patients who were referred to Imam Khomeini Hospital Complex was determined using quantitative Real-time PCR. Multiplex ligation-dependent probe amplification (MLPA) was conducted to evaluate the ERBB2 gene copy number

EXCLI journal2018 Full Text: Link to full Text with Trip Pro

205. Faslodex for Locally Advanced or Metastatic Breast Cancer – Details

Faslodex for Locally Advanced or Metastatic Breast Cancer – Details Faslodex for Locally Advanced or Metastatic Breast Cancer – Details | CADTH.ca Français Français Find the information you need Faslodex for Locally Advanced or Metastatic Breast Cancer – Details Faslodex for Locally Advanced or Metastatic Breast Cancer – Details Project Number pCODR 10110 Brand Name Faslodex Generic Name Fulvestrant Tumour Type Breast Indication Locally Advanced or Metastatic Breast Cancer Funding Request (...) For hormonal treatment of non-visceral locally advanced or metastatic breast cancer in postmenopausal women, regardless of age, who have not been previously treated with endocrine therapy Review Status Pending Pre Noc Submission Yes NOC Date Manufacturer AstraZeneca Canada Inc. Submitter AstraZeneca Canada Inc. Submission Date (Target Date) July 17, 2017 Submission Type New Drug Prioritization Requested Stakeholder Input Deadline (target date based on target submission date) ‡ July 31, 2017 Check-point

CADTH - Pan Canadian Oncology Drug Review2018

206. Melatonin inhibits the proliferation of breast cancer cells induced by bisphenol A via targeting estrogen receptor‐related pathways

Melatonin inhibits the proliferation of breast cancer cells induced by bisphenol A via targeting estrogen receptor‐related pathways ORIGINAL ARTICLE Melatonin inhibits the proliferation of breast cancer cells induced by bisphenol A via targeting estrogen receptor-related pathways Tianjiao Wang 1,2* , Bowen Liu 1* , Yanan Guan 2 , Miaomiao Gong 2 , Weiying Zhang 1 , Jinjin Pan 2 , Yanan Liu 2 , Rui Liang 2† , Yuhui Yuan 2 & Lihong Ye 1 1 State Key Laboratory of Medicinal Chemical Biology (...) , Department of Biochemistry, College of Life Sciences, Nankai University, Tianjin, China 2 Department of General Surgery, The Second Af?liated Hospital, Institute of Cancer Stem Cell, Dalian Medical University Cancer Center, Dalian, China Keywords Bisphenol A; breast neoplasms; estrogen response element; melatonin; steroid receptor coactivator. Correspondence Lihong Ye, State Key Laboratory of Medicinal Chemical Biology, Department of Cancer Research, Institute for Molecular Biology, College of Life

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

207. E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer

E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer REVIEWARTICLE OPEN E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer Sri Lakshmi Hyndavi Yeruva 1 , Fengmin Zhao 2 , Kathy D. Miller 3 , Amye J. Tevaarwerk 4 , Lynne I. Wagner 5 , Robert J. Gray 2 , Joseph A. Sparano 6 and Roisin M. Connolly 7 Endocrine (...) therapies are effective in the treatment of hormone receptor (HR)-positive breast cancer, however, de novo or acquired treatment resistance is a signi?cant clinical problem. A potential mechanism of resistance involves changes in gene expression secondary to epigenetic modi?cations, which might be reversed with the use of histone deacetylase (HDAC) inhibitors such as entinostat. The ENCORE 301 phase II randomized, placebo-controlled study demonstrated a signi?cant improvement in progression-free

NPJ breast cancer2018 Full Text: Link to full Text with Trip Pro

208. Kisqali for Metastatic Breast Cancer – Details

Kisqali for Metastatic Breast Cancer – Details Kisqali for Metastatic Breast Cancer – Details | CADTH.ca Find the information you need Kisqali for Metastatic Breast Cancer – Details Kisqali for Metastatic Breast Cancer – Details Project Number pCODR 10112 Brand Name Kisqali Generic Name Ribociclib Tumour Type Breast Indication Advanced or Metastatic Breast Cancer Funding Request For the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor (...) 2 (HER2)-negative advanced or metastatic breast cancer, as an initial endocrine-based therapy Review Status Open for Input on Submission Pre Noc Submission Yes NOC Date Manufacturer Novartis Pharmaceuticals Canada Inc. Submitter Novartis Pharmaceuticals Canada Inc. Submission Date October 17, 2017 Submission Type New Drug Prioritization Requested Not Requested Stakeholder Input Deadline ‡ October 31, 2017 Check-point meeting (target date) pERC Meeting (target date) Initial Recommendation Issued

CADTH - Pan Canadian Oncology Drug Review2018

209. Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012.

Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012. Importance: Given recent advances in screening mammography and adjuvant therapy (treatment), quantifying their separate and combined effects on US breast cancer mortality reductions by molecular subtype could guide future decisions to reduce disease burden. Objective: To evaluate the contributions associated with screening and treatment to breast cancer mortality reductions (...) by molecular subtype based on estrogen-receptor (ER) and human epidermal growth factor receptor 2 (ERBB2, formerly HER2 or HER2/neu). Design, Setting, and Participants: Six Cancer Intervention and Surveillance Network (CISNET) models simulated US breast cancer mortality from 2000 to 2012 using national data on plain-film and digital mammography patterns and performance, dissemination and efficacy of ER/ERBB2-specific treatment, and competing mortality. Multiple US birth cohorts were simulated. Exposures

JAMA2018 Full Text: Link to full Text with Trip Pro

210. Manganese‐12 acetate suppresses the migration, invasion, and epithelial–mesenchymal transition by inhibiting Wnt/β‐catenin and PI3K/AKT signaling pathways in breast cancer cells

Manganese‐12 acetate suppresses the migration, invasion, and epithelial–mesenchymal transition by inhibiting Wnt/β‐catenin and PI3K/AKT signaling pathways in breast cancer cells ORIGINAL ARTICLE Manganese-12 acetate suppresses the migration, invasion, and epithelial–mesenchymal transition by inhibiting Wnt/ß-catenin and PI3K/AKT signaling pathways in breast cancer cells Hongping Ju 1 , Yongxia Li 2 , Xiqian Xing 3 , Xisong Miao 1 , Yunping Feng 1 , Yunhui Ren 1 , Jing Qin 1 , Dian Liu 1 (...) , Zihao Chen 4 & Zhaoyu Yang 1 1 School of Medicine, Kunming University, Kunming, China 2 The Department of Respiratory Medicine, Second Ward, The Second Af?liated Hospital of Kunming Medical University, Kunming, China 3 The First Department of Respiratory Medicine, Yan’an Hospital Af?liated to Kunming Medical University, Kunming, China 4 The Graduate School, Hebei Medical University, Shijiazhuang, China Keywords Breast cancer; invasion; migration; manganese-12 acetate. Correspondence Zhaoyu Yang

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

211. Protocol for Moving On: a randomized controlled trial to increase outcome expectations and exercise among breast cancer survivors

Protocol for Moving On: a randomized controlled trial to increase outcome expectations and exercise among breast cancer survivors Nursing Open. 2018;5:101–108. | 101 wileyonlinelibrary.com/journal/nop2 R ec eiv ed: 16 F ebruary 2017 | A c c ep t ed: 21 O ct ober 2017 DOI: 10.1002/ nop2.119 STUDY PROTOCOL Protocol for Moving On: a randomized controlled trial to increase outcome expectations and exercise among breast cancer survivors Rachel Hirschey 1 | Gretchen Kimmick 2 | Marilyn Hockenberry 1 (...) sche y , D uk e U niv er sity S chool o f N ur sing, D urham, NC, US A. Email: hirschey@unc.edu Funding Information T his r esear ch is funded b y NINR 1F31NR015690-01 and O nc olo gy N ur sing S ocie ty F ounda tion Abstract Aim : The aim of this study was to test the feasibility and fidelity of an intervention, Moving On, aimed to increase outcome expectations OEs (i.e. what one expects to obtain or avoid as a result of a behaviour) and exercise among breast cancer survivors. Design : Randomized

Nursing open2018 Full Text: Link to full Text with Trip Pro

212. Breast Cancer Screening Behaviors of First Degree Relatives of Women Receiving Breast Cancer Treatment and the Affecting Factors

Breast Cancer Screening Behaviors of First Degree Relatives of Women Receiving Breast Cancer Treatment and the Affecting Factors Original Article Introduction Breast cancer is the most common cancer among females in Turkey. Incidence rate in the year 2008 was 40.7 in 100,000 and this rate increased to 43 in 2014 (1). Breast cancer incidence in Turkey is similar to the other developing countries but mortality is higher when compared with these countries (2). The best way to fight cancer (...) is to prevent its development by controlling the known risk factors. The most important risk factors for breast cancer are female gender, advancing age and family history. First-degree relatives (mother, sister and daughters) of women with breast cancer are at higher risk when compared with the general population and it has been reported that family history has a role in 5-10% of cases (3). Studies from T urkey have reported the genetic risk ranging from 5.4% to 25.9% (4-7). One study found that in all age

European journal of breast health2018 Full Text: Link to full Text with Trip Pro

213. Granulomatous Mastitis Concurrence with Breast Cancer

Granulomatous Mastitis Concurrence with Breast Cancer Case Report Address for Correspondence : Hasan Çalis, e-mail: drhasancalis@hotmail.com Received: 01.10.2017 Accepted: 07.11.2017 Eur J Breast Health 2018; 14: 58-60 DOI: 10.5152/ejbh.2017.3804 58 Introduction Idiopathic Granulomatous Mastitis (IGM) is a rare, chronic, non-malignant and non-life-threatening breast disease (1). Clinically and radiologically, it mimics carcinoma of the breast. The most common complaints of patients (...) are unilaterally emerging breast pain or painless masses (2, 3). This case highlights the possibility that the concurrence of chronic granulomatous mastitis with breast cancer may be explained just as an adjunct situation or a coincidence and may be the difficulty in distinguishing one from the other. Case Presentation A 77-year-old female was admitted to our clinic with complaints of breast pain, accompanied by edema and thickening of the skin at 9 o’clock of the right breast, close to the areola. Initial

European journal of breast health2018 Full Text: Link to full Text with Trip Pro

214. A Patient Advocacy Group Summit, Cancer Care in Turkey and The Society of Breast Health

A Patient Advocacy Group Summit, Cancer Care in Turkey and The Society of Breast Health Editorial According to the World Health Organization (WHO), cancer now causes more deaths than all cardiac or all other diseases (1). The num- ber of new cases is expected to rise by about 70% over the next 2 decades. Globally, nearly 1 in 6 deaths is due to cancer, and approximately 70% of deaths from cancer occur in low- and middle-income countries (2). There is a significant disparity in cancer care (...) cancer scientists in a way similar to The Society of Breast Health to perform basic, reliable, and reasonable clinical projects based on the economic, socio-cultural and educational structure of a country. The number of PAGs should be increased and representatives of them should be participated in governmental organizations (such as National cancer Advisory Board, National Cancer Institute, etc.) to advocate and acquire their rights. Their participation abso- lutely provides integrity in health care

European journal of breast health2018 Full Text: Link to full Text with Trip Pro

215. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer 28968163 2017 11 13 2017 11 13 1527-7755 35 32 2017 Nov 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. 3638-3646 10.1200/JCO.2017.75.6155 Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy and in combination with fulvestrant in women (...) with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with endocrine therapy. Methods MONARCH 3 is a double-blind, randomized phase III study of abemaciclib or placebo plus a nonsteroidal aromatase inhibitor in 493 postmenopausal women with HR-positive, HER2-negative advanced breast cancer who had no prior systemic therapy in the advanced setting. Patients received abemaciclib or placebo (150 mg twice daily continuous

EvidenceUpdates2018

216. FSRH CEU statement: study on contemporary hormonal contraception and the risk of breast cancer

FSRH CEU statement: study on contemporary hormonal contraception and the risk of breast cancer FSRH CEU statement: study on contemporary hormonal contraception and the risk of breast cancer - Faculty of Sexual and Reproductive Healthcare Privacy notice This site makes use of cookies . If you continue we'll assume you are happy to receive them. FSRH CEU statement: study on contemporary hormonal contraception and the risk of breast cancer FSRH CEU statement: study on contemporary hormonal (...) contraception and the risk of breast cancer Posted 12 December 2017 Site tools Date: 12 Dec 2017 Type: FSRH Statement An observational study published in the New England Journal of Medicine reports that, in the Danish study population, women who were currently using any method of hormonal contraception (HC) or had done so within the last 6 months were 20% more likely to be diagnosed with breast cancer than those who had never used HC. Another main finding is that the absolute increase in breast cancers

Faculty of Sexual & Reproductive Healthcare2018

217. Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer

Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer Ribociclib with an aromatase inhibitor for Ribociclib with an aromatase inhibitor for pre previously untreated, hormone receptor- viously untreated, hormone receptor- positiv positive, HER2-negativ e, HER2-negative, locally e, locally advanced or metastatic breast cancer advanced or metastatic breast cancer T echnology appraisal guidance (...) . Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 18Contents Contents 1 Recommendation 4 2 The technology 5 3 Committee discussion 6 Clinical management 6 Clinical evidence 7 Adverse events 8 The company's economic model 8 Progression-free survival state

National Institute for Health and Clinical Excellence - Technology Appraisals2018

218. Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer

Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer P Palbociclib with an aromatase inhibitor albociclib with an aromatase inhibitor for pre for previously untreated, hormone viously untreated, hormone receptor-positiv receptor-positive, HER2-negativ e, HER2-negative, locally e, locally advanced or metastatic breast cancer advanced or metastatic breast cancer T echnology appraisal guidance (...) . Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 24Contents Contents 1 Recommendations 4 2 The technology 5 3 Evidence 7 4 Committee discussion 8 Clinical management 8 Patient experience 9 Clinical effectiveness 9 Cost effectiveness 12 Summary of appraisal

National Institute for Health and Clinical Excellence - Technology Appraisals2018

219. Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202

Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202 29136387 2017 12 19 1527-7755 2017 Nov 14 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG (...) S1202. JCO2017746651 10.1200/JCO.2017.74.6651 Purpose Adherence to aromatase inhibitor (AI) therapy for early-stage breast cancer is limited by AI-associated musculoskeletal symptoms (AIMSS). Duloxetine is US Food and Drug Administration approved for treatment of multiple chronic pain disorders. We hypothesized that treatment of AIMSS with duloxetine would improve average joint pain compared with placebo. Methods This randomized, double-blind, phase III trial included AI-treated postmenopausal women

EvidenceUpdates2018 Full Text: Link to full Text with Trip Pro

220. Metastatic breast cancer

Metastatic breast cancer Metastatic breast cancer - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Metastatic breast cancer Last reviewed: August 2018 Last updated: April 2018 Summary There is great heterogeneity in both the presentation and prognosis of metastatic breast cancer. Multi-gene expression panels are being evaluated to determine which women with early stage breast cancer are more likely to develop (...) metastatic disease. Decisions on whether or not to treat a patient with metastatic breast cancer and the aggressiveness of treatment must be individualised, based on patient prognosis, tumour characteristics, performance status, and the primary goals of treatment. Unlike stage I to III breast cancer, the primary goal of treatment in metastatic breast cancer is often to improve quality of life, with extending life a secondary goal. Definition Breast cancer is considered metastatic breast cancer (MBC

BMJ Best Practice2018